KEY TAKEAWAYS The phase 3 trial aimed to investigate the efficacy of tisotumab vedotin as a 2- or 3L treatment in patients with recurrent cervical cancer. The primary end point was to determine OS. Researchers noticed significantly greater efficacy of tisotumab...